按抗体特异性对ANCA相关性血管炎亚分组在临床病理分类之外的临床影响
该回顾性单中心研究纳入150例ANCA相关性血管炎患者(94例GPA、56例MPA;87例抗PR3、63例抗MPO),评估基于临床病理标准和/或ANCA特异性重新分类的影响。结果显示GPA患者无复发生存更差但肾脏生存更好,而抗PR3与抗MPO患者间总体预后相似,抗MPO GPA亚组未带来额外临床价值。
要点
- 临床病理分类(GPA vs MPA)是区分预后同质人群的最强标准。
- 抗PR3与抗MPO患者总体无复发生存、肾脏生存率相似。
- 单独划分抗MPO GPA亚组未显示额外临床价值。
核心结论
- 临床病理分类似乎是区分ANCA相关性血管炎同质预后的最强标准。
- 单独划分抗MPO GPA亚组似乎未给临床实践带来额外价值,但需多中心研究证实。
研究设计与样本
- 回顾性单中心研究,在Caen大学医院开展,纳入2000年1月或2011年9月至2016年6月的PR3或MPO-ANCA AAV患者,排除嗜酸性GPA。
- 共纳入150例AAV患者(94例GPA、56例MPA;87例抗PR3、63例抗MPO),并按欧洲药品管理局血管炎算法分类为GPA或MPA。
主要发现
- GPA患者较MPA患者无复发生存更差(P < 0.001)但肾脏生存更好(P = 0.021)。
- 抗PR3与抗MPO患者总体无复发生存、肾脏生存率相似(P = 0.35、0.17、0.15)。
- 抗MPO MPA与抗PR3 MPA患者预后相同(P = 0.33、0.19、0.65)。
- 抗MPO GPA与抗PR3 GPA患者预后相同(P = 0.06、0.99、0.64)。
- 抗PR3 GPA与抗MPO GPA患者在临床表现或BVAS评分上无差异。
临床怎么用
- 临床实践中可优先依据临床病理分类(GPA vs MPA)判断AAV预后。
- 不建议仅凭抗MPO特异性单独划分GPA亚组来指导临床决策。
局限性
- 为回顾性单中心研究,结论需多中心研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In ANCA-associated vasculitis (AAV), classifications have emerged to individualize homogeneous clinical and outcomes patterns, including the recently defined anti-MPO granulomatosis with polyangiitis (GPA) subgroup. This study aimed to retrospectively evaluate the impacts of re-classification based on clinicopathological criteria and/or ANCA specificity. METHODS: A retrospective monocentric study conducted at Caen University Hospital led to the identification of PR3 or MPO-ANCA AAV patients from January 2000 or September 2011, respectively, to June 2016. Eosinophilic GPA patients were excluded. AAVs were thereby also classified either as GPA or microscopic polyangiitis (MPA) according to the European Medicines Agency vasculitis algorithm. RESULTS: A total of 150 AAV patients were included (94 GPA, 56 MPA; 87 anti-PR3 and 63 anti-MPO patients). GPA patients exhibited a worse relapse-free survival but a better renal survival (P < 0.001 and P = 0.021, respectively) than MPA patients. Overall, relapse-free and renal survival rates were similar between anti-PR3 and anti-MPO patients (P = 0.35, 0.17 and 0.15, respectively). Similarly, the prognosis was identical between anti-MPO MPA patients and anti-PR3 MPA patients (P = 0.33, 0.19 and 0.65, respectively), and between anti-MPO GPA patients and anti-PR3 GPA patients (P = 0.06, 0.99 and 0.64, respectively). Moreover, anti-PR3 GPA and anti-MPO GPA patients exhibited no differences in clinical manifestations or BVAS score. CONCLUSION: Clinicopathological classification appeared to be the strongest criterion for distinguishing among homogeneous prognoses of AAV. Individualizing the anti-MPO GPA subgroup does not appear to bring additional value to clinical practice, but multicentre studies are required to confirm this trend.
引用
- Deshayes S, Martin Silva N, Khoy K, et al. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford). 2019. PMID: 30805643. doi:10.1093/rheumatology/kez016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。